Кларитромицин-Тева (Clarithromycin) is a macrolide antibiotic that is generally used for managing a variety of bacterial infections. It is applied across therapeutic domains for infections in many areas of the body, which helps address symptom clusters that may become intense or disruptive. The medicine is commonly used for infections of the lungs (such as pneumonia and bronchitis), ears, sinuses, throat, and skin. This supports the patient during difficult episodes by easing distress related to physical discomfort and systemic imbalance.

This medication is also relevant for easing symptoms associated with acute or episodic changes. It is commonly used as part of combination therapy applied in managing Helicobacter pylori (related to duodenal ulcers) and plays a role in managing and supporting the treatment of Mycobacterium avium complex (MAC) infection, which are conditions involving episodic or fluctuating manifestations. For patients needing supportive relief during acute phases, it provides support that helps ease the overall symptom burden.

“This medication is commonly used across conditions presenting with acute episodes and provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Supports Comfort During Periods of Physical Discomfort

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Кларитромицин-Тева (Clarithromycin)

The use of Кларитромицин-Тева is strictly governed by population eligibility rules outlined in regulatory labeling. The medicine is generally permitted for use in adults and adolescents 12 years and older. Eligibility is defined by specific exclusions, restrictions, and age limitations.

---

Absolute Contraindications (Must Not Use)

Condition / Population	Status
Hypersensitivity to macrolide antibiotics	Contraindicated
History of QT prolongation or ventricular arrhythmia	Contraindicated
History of cholestatic jaundice from prior use	Contraindicated
Severe hepatic failure combined with renal impairment	Contraindicated
Uncorrected hypokalaemia or hypomagnesaemia	Contraindicated

---

Restrictions and Limitations

• Children under 12 years: The film-coated tablets are not recommended; the liquid suspension formulation is typically used for this age group.
• Infants under 6 months: Safety and efficacy have not been established.
• Severe Renal Impairment (CrCl < 30 mL/min): Use is conditional, requiring a mandatory 50% dosage reduction.
• Pregnancy and Lactation: Use is not recommended; benefits must clearly outweigh risk in pregnancy, and safety is not established for breastfed infants. Caution is also advised for patients with pre-existing cardiac conditions like severe cardiac insufficiency or conduction disturbances.

Interactions with other medicines and products

Кларитромицин-Тева interacts with numerous medicinal products, primarily because it is documented as a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) drug transporter. This pharmacokinetic interaction pattern leads to significantly increased plasma concentrations and reduced clearance of co-administered substances. The regulatory label defines specific combinations that are strictly prohibited.

The following medicines are contraindicated (co-administration prohibited):

• Astemizole, Cisapride, Pimozide, and Terfenadine: Due to the documented risk of QT prolongation and cardiac arrhythmias.
• Lovastatin and Simvastatin: Due to the increased risk of myopathy, including rhabdomyolysis.
• Ergot Alkaloids (Ergotamine, Dihydroergotamine): Due to the risk of acute ergot toxicity.
• Lomitapide and Lurasidone: Due to potential for markedly increased exposure and serious adverse reactions.

For some interactions, the constraint is population-specific: the combination with Colchicine is strictly contraindicated in patients with renal or hepatic impairment. Other drug exposures are officially increased, such as the documented 7-fold increase in the AUC of oral Midazolam. Additionally, the herbal product St. John's Wort is listed as an inducer that may reduce Clarithromycin levels. Finally, the regulatory requirements specify that the extended-release tablet formulation must be taken with food.

Blocking the Bacterial Protein Synthesis Pathway

Кларитромицин-Тева exerts its primary effect by engaging with the 50S ribosomal subunit of susceptible bacteria, binding to the 23S ribosomal RNA (rRNA) component near the peptidyl transferase center. This molecular interaction physically blocks the exit tunnel required for new peptide chains to emerge, halting the elongation of essential proteins . This targeted action suppresses the bacteria's ability to replicate and sustain its vital functions, leading to a core bacteriostatic effect that arrests the infectious proliferation, enabling the host's natural immune processes to neutralize the microbial population.

---

️ Mechanisms of Resistance and Functional Limits

The functional effectiveness of this mechanism is constrained by bacterial counter-mechanisms. Specifically, some microbes develop resistance either through active efflux—pumps that transport the drug out of the cell—or by target site modification, where enzymatic methylation of the 23S rRNA reduces the drug’s binding affinity. These adaptations prevent the drug from achieving the ribosomal blockade necessary to induce the bacteriostatic effect, thus compromising the inhibition of bacterial proliferation.

The administration of Кларитромицин-Тева is governed by official regulatory protocols that define the route, schedule, and specific conditions for intake. The medicine is administered exclusively via the oral route, available as immediate-release (IR) tablets, extended-release (ER) tablets, and an oral suspension.

Official Administration Guidelines

Instruction	Official Rule
Route and Form	Oral; available as IR tablets, ER tablets, and oral suspension.
Standard Dosing	Adult IR dose is typically 250 mg to 500 mg per administration. ER dose is typically 1000 mg once daily.
Frequency and Timing	IR forms are taken twice daily (every 12 hours). ER forms are taken once daily (every 24 hours).
Meal Relationship	IR tablets and suspension may be taken with or without food. ER tablets must be taken with food.
Handling	ER tablets must be swallowed whole; they cannot be crushed, broken, or chewed.
Duration	The standard treatment course is typically 6 to 14 days.

Population and Procedural Constraints

For patients experiencing severe renal impairment (creatinine clearance < 30 mL/ min), official instructions require the dose to be reduced by 50% of the standard amount. Furthermore, the treatment course for these patients is restricted to a maximum of 14 days. Pediatric use is managed with the oral suspension, as tablets are generally not recommended for children under 12 years. If a dose is missed, the patient should take it as soon as the lapse is noted, but they must not double the subsequent dose to compensate for the oversight. This structured protocol ensures the standardized and label-aligned use of the medication.

Research evidence / Overview of studies for Кларитромицин-Тева

Кларитромицин-Тева contains the established active ingredient Clarithromycin, for which numerous clinical trials have been conducted. The evidence base primarily consists of Comparative Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. The overall purpose of this research is to explore patterns observed in the studies across its studied applications.

---

Evidence for Use in Acute Respiratory and Skin Infections

Research was studied for its use in specific conditions that were investigated, such as bacterial pharyngitis, acute exacerbations of chronic bronchitis, certain pneumonias, and mild-to-moderate skin infections.

Researchers utilized short-term RCTs to assess the research profile of Clarithromycin in patient populations that included Adults, Adolescents, and Pediatric groups. These trials primarily monitored two types of outcomes: clinical outcomes, which focuses on symptom changes, and microbiological outcomes, which tracks the presence of the susceptible target pathogen. Findings describe patterns observed in these short-term studies, where research explored short-term symptom changes and outcomes related to systemic or functional imbalance.

---

Evidence for the Eradication of H. pylori

Clarithromycin was studied for its role as a key component in a multi-drug regimen (often triple therapy) in research examining the pathogen status of **Helicobacter pylori bacteria**, which is linked to duodenal ulcers.

Studies primarily involved Multicenter Controlled Trials on Adult patients with confirmed H. pylori infection. Research examined pathogen eradication rates, and some trials also monitored related outcomes, such as ulcer healing. The research base supporting this specific application is generally considered Moderate-level.

---

What is Still Uncertain About Clarithromycin

The evidence highlights what is known—and what is still uncertain—within the research landscape. A key uncertainty stems from the fact that antibiotic research is constantly impacted by emerging resistance. For both acute infections and H. pylori eradication, research is ongoing to address the variable success rates associated with the presence of resistant bacterial strains. Furthermore, the existing research provides limited insight into long-term outcomes after patients completed the study period. Study results reflect the specific conditions under which they were conducted and research provides context but not individual predictions.

Key Studies & References

1. Clarithromycin Monograph: Information for Patients
2. Macrolides and Lincosamides: National Library of Medicine Review

Common questions about Кларитромицин-Тева (FAQ)

---

Q: What's the difference between Кларитромицин-Тева and standard clarithromycin?

Кларитромицин-Тева is a branded generic medicine that contains the active ingredient Clarithromycin. According to regulatory standards, branded generic products are manufactured to contain the same active ingredient and are approved for the same medical uses as the original reference product.

---

Q: Are there any known interactions between Кларитромицин-Тева and alcohol?

Official regulatory documents do not list a specific, direct interaction between Clarithromycin and alcohol that would significantly impact the drug's safety or how well it works. Patients should discuss alcohol consumption with their healthcare provider.

---

Q: Is Кларитромицин-Тева safe for older adults?

The medicine is approved for use in adults. Official safety information advises caution for older adults because they may have a higher risk of drug interactions or increased side effects, especially if they have underlying issues with their liver or kidneys.

---

Q: Is it okay to take pain relievers like ibuprofen with Кларитромицин-Тева?

Regulatory drug labels generally do not report a direct pharmacokinetic interaction between Clarithromycin and common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. It is important that patients have a healthcare professional review all medications they are currently taking.

---

Q: How quickly does Кларитромицин-Тева start working after the first dose?

Official pharmacokinetic data indicates that Clarithromycin is absorbed rapidly after being taken by mouth. Peak concentrations of the medicine in the bloodstream are typically reached within about 2 to 3 hours after taking an immediate-release tablet.

---

Q: Does taking Кларитромицин-Тева increase sensitivity to the sun?

Phototoxicity, which is increased skin sensitivity to sunlight, is not commonly or uncommonly listed as a reported adverse reaction in the official regulatory documents for Clarithromycin.

---

Q: Is a temporary change in bowel habits normal while on Кларитромицин-Тева?

Yes, regulatory data indicates that gastrointestinal disturbances are commonly reported. These can include diarrhea, abdominal pain, and nausea. These are known side effects reported in clinical data.

---

Q: How is Кларитромицин-Тева generally eliminated from the body?

The medicine is removed from the body primarily through two routes. It is first metabolized (broken down) by the liver and then excreted through both the urine and the feces.

---

Q: Are there different strengths or formulations of Кларитромицин-Тева available?

Yes, official dosage form information shows that Clarithromycin is available in multiple forms. These typically include immediate-release and extended-release tablets, as well as an oral suspension formulation.

---

Q: Can I take a probiotic supplement while using Кларитромицин-Тева?

While regulatory documents don't list a direct drug interaction, the antibiotic can potentially affect the effectiveness of probiotics. Healthcare professionals may advise on the appropriate timing between taking the antibiotic and any supplement.

---

Q: What is the half-life of Кларитромицин-Тева in the body?

The half-life of the drug, which is the time it takes for half the drug to be eliminated from the bloodstream, varies based on the dose taken. It generally ranges from 3 to 4 hours for a standard 250 mg dose, and longer for higher doses.

---

Q: Does Кларитромицин-Тева interact with blood thinners like warfarin?

Yes, official labeling confirms a significant interaction with anticoagulants like warfarin. Clarithromycin can increase the blood thinning effect, which raises the risk of bleeding. This combination requires careful medical monitoring of blood clotting measures (INR).

---

Q: Can Кларитромицин-Тева be used to treat ear infections?

Yes, the medicine is officially indicated for the treatment of Acute Otitis Media, which is a type of ear infection. This treatment is used when the infection is caused by susceptible strains of bacteria.

---

Q: Does Кларитромицин-Тева affect liver function tests?

Yes, regulatory safety data indicates that abnormal liver function test results are a common adverse reaction. There have also been reports of increased liver enzymes and hepatitis associated with the use of the medicine.

---

Q: Can Кларитромицин-Тева be taken with dairy products?

Official administration instructions state that immediate-release tablets and the suspension can be taken with or without food. Unlike some other antibiotic classes, regulatory documents do not specify avoiding dairy products with Clarithromycin.

---

Q: Is it common to feel unusually tired while taking Кларитромицин-Тева?

Official documents list general discomfort (malaise) and drowsiness (somnolence) as uncommon adverse reactions. If any adverse reaction, including unusual tiredness, becomes severe or persistent, medical advice should be sought.

---

Q: Does research support the use of Кларитромицин-Тева for chronic conditions?

Yes, the official indications include the treatment and prevention (prophylaxis) of a specific chronic infection called disseminated Mycobacterium avium Complex (MAC) disease, which occurs in certain patients with advanced HIV infection.

---

Q: What steps should I take if I experience severe diarrhea while on Кларитромицин-Тева?

Official warnings note that severe or persistent diarrhea, even after the course is finished, may be a sign of a serious condition called Clostridioides difficile-associated diarrhea (CDAD). If severe or watery diarrhea occurs, immediate medical assessment is required.

---

Q: Are there specific vitamins or supplements that interact with Кларитромицин-Тева?

The regulatory label specifically warns that the herbal supplement St. John's Wort may reduce the amount of Clarithromycin in the blood. No common vitamins are listed as having a significant interaction.

---

Q: What are the different types of infections Кларитромицин-Тева is approved to treat?

The drug is officially approved to treat bacterial infections across multiple body systems. These include infections of the respiratory tract (such as certain pneumonias), the skin and soft tissue, and the treatment regimen for H. pylori bacteria that cause stomach ulcers.

---

Q: How does the mechanism of action of Кларитромицин-Тева compare to penicillin?

Clarithromycin is a macrolide antibiotic that works by stopping bacteria from making essential proteins. In contrast, penicillin is a beta-lactam antibiotic that works by preventing bacteria from building their cell walls. These are two distinct classes of antibiotics.

---

Q: Is Кларитромицин-Тева a broad-spectrum or narrow-spectrum antibiotic?

Official regulatory documents and microbiology data describe Clarithromycin as having a broad spectrum of activity. This means it is effective against a wide range of different bacteria, including both Gram-positive and Gram-negative types.

---

Q: What common OTC cold and flu medicines might interact with Кларитромицин-Тева?

The label specifically prohibits taking Clarithromycin with certain older antihistamines (like astemizole or terfenadine) due to the risk of serious heart issues. It is important that any medicine metabolized by the CYP3A4 enzyme is reviewed with a healthcare provider before combination.

---

Q: Is it possible to become resistant to Кларитромицин-Тева over time?

Yes, official warnings confirm that the drug’s effectiveness is affected by the development of bacterial resistance. Infections caused by bacteria known to be resistant to Clarithromycin require different treatment approaches.

---

Q: Why is Кларитромицин-Тева sometimes given as part of combination therapy?

Clarithromycin is explicitly indicated for use as a key component in triple therapy (three-drug regimen) to effectively eradicate H. pylori bacteria, which is the primary cause of many duodenal ulcers.

---

Q: Is it normal to have vivid dreams while taking this medication?

Official post-marketing surveillance reports, classified under psychiatric adverse events, have included incidents of nightmares. While not common, unusual dreams or nightmares are a reported effect.

---

Q: Does grapefruit juice affect the absorption of Кларитромицин-Тева?

Studies on the interaction of grapefruit juice suggest it may delay the time it takes for the drug to reach its peak concentration in the blood. However, official regulatory labeling does not typically require the specific avoidance of grapefruit juice.

---

Q: Can Кларитромицин-Тева be used for prophylaxis (preventative treatment) in some cases?

Yes, regulatory documents indicate Clarithromycin is approved for prophylaxis—which means preventative treatment—against disseminated Mycobacterium avium Complex (MAC) disease in patients with advanced HIV infection.

Storage and Disposal of Clarithromycin-Teva

Clarithromycin-Teva, in tablet form, must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).

Form-Specific Requirements

• Tablets: Protect from excess heat and moisture. The container must be kept tightly closed.
• Oral Suspension (Reconstituted): Store at 15 C to 30 C. The suspension must not be refrigerated and any unused portion must be discarded after 14 days.

Safety and Disposal

All forms of the medicine must be stored out of the sight and reach of children.

Disposal of unused or expired product should preferentially be through a drug take-back program. If one is unavailable, the medicine should be mixed with an unpalatable substance (such as dirt) in a sealed container and placed in the household trash; do not flush the product.